Outcome of patients receiving a continuous flow left ventricular assist device - a retrospective single center study

Show full item record



Permalink

http://hdl.handle.net/10138/329056

Citation

Kiss , J , Stark , C , Nykaäen , A & Lemström , K 2020 , ' Outcome of patients receiving a continuous flow left ventricular assist device - a retrospective single center study ' , Scandinavian Cardiovascular Journal , vol. 54 , no. 4 , pp. 212-219 . https://doi.org/10.1080/14017431.2020.1751264

Title: Outcome of patients receiving a continuous flow left ventricular assist device - a retrospective single center study
Author: Kiss, Jan; Stark, Christoffer; Nykaäen, Antti; Lemström, Karl
Other contributor: University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Transplantation Laboratory
University of Helsinki, HUSLAB







Date: 2020-08
Language: eng
Number of pages: 8
Belongs to series: Scandinavian Cardiovascular Journal
ISSN: 1401-7431
DOI: https://doi.org/10.1080/14017431.2020.1751264
URI: http://hdl.handle.net/10138/329056
Abstract: Objectives. We present the outcome of the first 80 patients receiving a continuous flow left ventricular assist device at Helsinki University Hospital between December 2011 and November 2018. Design. This was a single-center retrospective study. We describe our patient management in detail. The primary end-points were death, heart transplantation, or pump explant. Data was reported in accordance with the Interagency Registry for Mechanical Circulatory Support protocol. All patients receiving an assist device during the study period were included in the data analysis. Results. Mean patient age was 53 +/- 12 years at implantation and 85% were male. Most patients suffered from dilated (48%), or ischemic (40%) cardiomyopathy. One-third of patients were bridged with venoarterial extracorporeal membrane oxygenation to assist device implantation. Implant strategy was bridge to transplant or bridge to decision in most patients (88%). Mean follow-up time on pump was 529 +/- 467 days. Survival was 98, 92, 85, 79 and 71% at 1, 3, 12, 24 and 36 months, respectively. Most common causes of death were multi-organ failure, right heart failure, or stroke. Only three patients (4%) had suspected pump thrombosis, two of which resolved with medical treatment and one resulting in death. Pump exchange or explant were not performed in a single patient. Neurological events occurred in 18%, non-disabling stroke in 8%, and fatal stroke in 4% of the patients. The incidence of device-related infection was 10%. Conclusions. Survival rates were good, although one third of patients were bridged with temporary circulatory support. We report a high level of freedom from pump thrombosis, fatal stroke, and driveline infection.
Subject: CF LVAD
mortality
stroke
infection
pump thrombosis
HEART
REGISTRY
TRANSPLANTATION
EVALUATE
SUPPORT
SOCIETY
3126 Surgery, anesthesiology, intensive care, radiology
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Heartware_Stark_2_.pdf 448.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record